Angiogenesis and survival in patients with myelodysplastic syndrome

Pathology and Oncology Research

Volumn 18, Issue 3, 2012, Pages 681-690

  Savic, Aleksandar ^a   Cemerikic Martinovic, Vesna ^b   Dovat, Sinisa ^c   Rajic, Nebojsa ^a   Urosevic, Ivana ^a   Sekulic, Borivoj ^a   Kvrgic, Vanja ^a   Popovic, Stevan ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b Pathohistology Laboratory Beolab   (Serbia)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Microvessel density; Myelodysplastic syndrome; Prognosis; Survival; VEGF

Indexed keywords

VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD TRANSFUSION; BLOOD VESSEL PARAMETERS; BONE MARROW BIOPSY; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENETIC RISK; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROVESSEL DENSITY; MYELODYSPLASTIC SYNDROME; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL; SURVIVAL TIME; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICROCIRCULATION; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863975376     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-012-9495-y     Document Type: Article

References (39)

1. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med 1:27-31
2. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
3. Padro T, Ruiz S, Bieker R et al (2000) Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95:2637-2644
4. Hussong JW, Rodgers JM, Shami PJ (2000) Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95:309-313
5. Lundberg LG, Lerner R, Sundelin P et al (2000) Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 157:15-19
6. Mesa RA, Hanson CA, Rajkumar SV et al (2000) Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 96:3374-3380
7. Peterson L, Kini AR (2001) Angiogenesis is increased in B-cell chronic lymphocytic leukemia. Blood 97:2529
8. Rajkumar SV, Leong T, Roche PC et al (2000) Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 6:3111-3116
9. Aguayo A, Kantarjian H, Manshouri T et al (2000) Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96:2240-2245
10. Pruneri G, Bertolini F, Soligo D et al (1999) Angiogenesis in myelodysplastic syndromes. Br J Cancer 81:1398-1401
11. Korkolopoulou P, Apostolidou E, Pavlopoulos PM et al (2001) Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia 15:1369-1376
12. Lundberg LG, Hellstrom-Lindberg E, Kanter-Lewensohn L et al (2006) Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes. Leuk Res 30:247-253
13. Alexandrakis MG, Passam FH, Pappa CA et al (2005) Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes. Leuk Res 29:41-46
14. Gale NW, Yancopoulos GD (1999) Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 13:1055-1066
15. Bellamy WT, Richter L, Sirjani D et al (2001) Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 97:1427-1434
16. Wimazal F, Krauth MT, Vales A et al (2006) Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. Leuk Lymphoma 47:451-460
17. Bennett JM, Catovsky D, Daniel MT et al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199
18. Brunning RD, Orazi A, Germing U et al (2008) Myelodysplastic syndromes/Neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 88-93
19. Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088
20. Thiele J, Kvasnicka HM, Facchetti F et al (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90:1128-1132
21. Tricot G, De Wolf-Peeters C, Vlietinck R et al (1984) Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol 58:217-225
22. Perez-Atayde AR, Sallan SE, Tedrow U et al (1997) Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 150:815-821
23. Keith T, Araki Y, Ohyagi M et al (2007) Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia. Br J Haematol 137:206-215
24. Malcovati L, Germing U, Kuendgen A et al (2007) Timedependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510
25. Verstovsek S, Estey E, Manshouri T et al (2002) Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 118:151-156
26. Gabrilove J (2001) Angiogenic growth factors: autocrine and paracrine regulation of survival in hematologic malignancies. Oncologist 6(Suppl 5):4-7
27. Dias S, Hattori K, Zhu Z et al (2000) Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 106:511-521
28. Padro T, Bieker R, Ruiz S et al (2002) Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 16:1302-1310
29. Germing U, Hildebrandt B, Pfeilstöcker M et al (2005) Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 19:2223-2231
30. Sperr WR, Wimazal F, Kundi M et al (2001) Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. Ann Hematol 80:272-277
31. Horny HP, Sotlar K, Valent P (2007) Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. Leuk Res 31:1609-1616
32. Valent P, Horny HP, Bennett JM et al (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 31:727-736
33. Patsouris E, Katsarou O, Korkolopoulou P et al (2004) Increased microvascular network in bone marrow of HIV-positive haemophilic patients. HIV Med 5:18-25
34. List A, Dewald G, Bennett J et al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465
35. Raza A, Reeves JA, Feldman EJ et al (2008) Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate- 1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111:86-93
36. Musto P (2004) Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res 28:325-332
37. Giles FJ, Stopeck AT, Silverman LR et al (2003) SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 102:795-801
38. Giles FJ, Bellamy WT, Estrov Z et al (2006) The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res 30:801-811
39. Oh ST, Gotlib J (2008) Antiangiogenic therapy in myelodysplastic syndromes: is there a role? Curr Hematol Malig Rep 3:10-18